{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:19:04Z","timestamp":1792271944997,"version":"4.4.0"},"reference-count":57,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Purpura fulminans (PF) is a rare but devastating complication of sepsis characterized by a highly thrombotic subtype of disseminated intravascular coagulation (DIC). A medical emergency, PF often requires the involvement of consultant hematologists to assist with diagnosis and management of patients who are in a highly dynamic and deteriorating clinical situation. Patients who survive past the first 24 to 72 hours often die from complications of unchecked thrombosis rather than shock, and survivors are usually left with severe scarring and tissue loss. Despite these challenging features, PF is a pathophysiologically distinct, homogeneous, and highly predictable form of sepsis-associated DIC for which poor outcomes are not a foregone conclusion. The fundamental pathologic lesion in PF is a failure of the anticoagulant protein C pathway, which leads to uncontrolled microvascular clotting and inadequate protein C\u2013mediated cytoprotective effects, which are vital for survival in sepsis. Herein, we review the clinical features and diagnosis of PF. Drawing from existing clinical literature and recent advances in our understanding of the pathophysiology of PF, we describe rationally designed treatment approaches for this disorder, including repletion of natural circulating anticoagulants, use of therapeutic anticoagulation, and ways to optimize transfusion support, and we outline specific interventions that we would recommend avoiding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024025078","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T14:05:48Z","timestamp":1735567548000},"page":"1358-1368","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["How I diagnose and treat acute infection\u2013associated purpura fulminans"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0754-7688","authenticated-orcid":false,"given":"Pavan K.","family":"Bendapudi","sequence":"first","affiliation":[{"name":"1Division of Hematology and Blood Transfusion Service, Massachusetts General Hospital, Boston, MA"},{"name":"2Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Boston, MA"},{"name":"3Center for the Development of Therapeutics, The Broad Institute of MIT and Harvard, Cambridge, MA"},{"name":"4Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3790-2660","authenticated-orcid":false,"given":"Julie-Aurore","family":"Losman","sequence":"additional","affiliation":[{"name":"4Harvard Medical School, Boston, MA"},{"name":"5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"6Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2025032715214569100_bib1","volume-title":"StatPearls","author":"Perera","year":"17, 2023"},{"issue":"6","key":"2025032715214569100_bib2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.siny.2011.07.009","article-title":"Diagnosis and management of neonatal purpura fulminans","volume":"16","author":"Price","year":"2011","journal-title":"Semin Fetal Neonatal Med"},{"issue":"22","key":"2025032715214569100_bib3","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199111283252207","article-title":"Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate","volume":"325","author":"Dreyfus","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025032715214569100_bib4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/bloodadvances.2021005126","article-title":"Idiopathic purpura fulminans associated with anti-protein S antibodies in children: a multicenter case series and systematic review","volume":"6","author":"Theron","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2025032715214569100_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40425-019-0582-4","article-title":"Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report","volume":"7","author":"Honjo","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"10446","key":"2025032715214569100_bib6","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1016\/S0140-6736(24)01178-4","article-title":"Multi-system involvement-including purpura fulminans-as an adverse effects of immune checkpoint inhibitor therapy for clear cell renal cell carcinoma","volume":"403","author":"Wirbel","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"2025032715214569100_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.tmrv.2017.10.001","article-title":"Purpura fulminans: mechanism and management of dysregulated hemostasis","volume":"32","author":"Colling","year":"2018","journal-title":"Transfus Med Rev"},{"issue":"3","key":"2025032715214569100_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1525-1470.1998.1998015169.x","article-title":"Acute infectious purpura fulminans: pathogenesis and medical management","volume":"15","author":"Darmstadt","year":"1998","journal-title":"Pediatr Dermatol"},{"issue":"9","key":"2025032715214569100_bib9","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1056\/NEJM198708273170912","article-title":"Purpura fulminans in meningococcemia: association with acquired deficiencies of proteins C and S","volume":"317","author":"Powars","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025032715214569100_bib10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/clinids\/17.2.254","article-title":"Epidemic meningococcemia and purpura fulminans with induced protein C deficiency","volume":"17","author":"Powars","year":"1993","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2025032715214569100_bib11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJM200108093450603","article-title":"Dysfunction of endothelial protein C activation in severe meningococcal sepsis","volume":"345","author":"Faust","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2025032715214569100_bib12","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201302-0228OC","article-title":"Assessment of the interplay between blood and skin vascular abnormalities in adult purpura fulminans","volume":"188","author":"Lerolle","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"21","key":"2025032715214569100_bib13","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1182\/bloodadvances.2018024430","article-title":"Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentrate","volume":"2","author":"Bendapudi","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"2025032715214569100_bib14","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1097\/01.CCM.0000072121.61120.D8","article-title":"Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study","volume":"31","author":"de Kleijn","year":"2003","journal-title":"Crit Care Med"},{"issue":"5","key":"2025032715214569100_bib15","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1538-7836.2005.01267.x","article-title":"Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma","volume":"3","author":"Ohlin","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"2025032715214569100_bib16","first-page":"614545","article-title":"Thrombomodulin: a bifunctional modulator of inflammation and coagulation in sepsis","volume":"2012","author":"Okamoto","year":"2012","journal-title":"Crit Care Res Pract"},{"issue":"4","key":"2025032715214569100_bib17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/SHK.0b013e318204c019","article-title":"Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial","volume":"35","author":"Aikawa","year":"2011","journal-title":"Shock"},{"issue":"1","key":"2025032715214569100_bib18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","article-title":"Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial","volume":"5","author":"Saito","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"2025032715214569100_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJM198808183190703","article-title":"Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura","volume":"319","author":"Girardin","year":"1988","journal-title":"N\u00a0Engl J Med"},{"issue":"8529","key":"2025032715214569100_bib20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(87)91728-4","article-title":"Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease","volume":"1","author":"Waage","year":"1987","journal-title":"Lancet"},{"issue":"3","key":"2025032715214569100_bib21","first-page":"1","article-title":"Pathogenesis of meningococcal purpura fulminans","volume":"75","author":"Lecuyer","year":"2017","journal-title":"Pathog Dis"},{"issue":"3","key":"2025032715214569100_bib22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.thromres.2013.12.031","article-title":"Microparticle-associated tissue factor activity correlates with plasma levels of bacterial lipopolysaccharides in meningococcal septic shock","volume":"133","author":"Hellum","year":"2014","journal-title":"Thromb Res"},{"issue":"25","key":"2025032715214569100_bib23","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1182\/blood.2023021166","article-title":"Rethinking coagulation: from enzymatic cascade and cell-based reactions to a convergent model involving innate immune activation","volume":"142","author":"Yong","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2025032715214569100_bib24","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1111\/j.1538-7836.2011.04422.x","article-title":"Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation","volume":"9","author":"Ammollo","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"2025032715214569100_bib25","doi-asserted-by":"crossref","first-page":"e0156763","DOI":"10.1371\/journal.pone.0156763","article-title":"Histones induce the procoagulant phenotype of endothelial cells through tissue factor up-regulation and thrombomodulin down-regulation","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"2025032715214569100_bib26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4161\/viru.26515","article-title":"Meningococcal disease and the complement system","volume":"5","author":"Lewis","year":"2014","journal-title":"Virulence"},{"issue":"7","key":"2025032715214569100_bib27","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","article-title":"Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults","volume":"130","author":"Konar","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2025032715214569100_bib28","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.molimm.2009.04.027","article-title":"The role of the anaphylatoxins in health and disease","volume":"46","author":"Klos","year":"2009","journal-title":"Mol Immunol"},{"issue":"8832","key":"2025032715214569100_bib29","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/0140-6736(92)92561-S","article-title":"Meningococcal septicaemia in a C6-deficient patient and effects of plasma transfusion on lipopolysaccharide release","volume":"340","author":"Lehner","year":"1992","journal-title":"Lancet"},{"issue":"4","key":"2025032715214569100_bib30","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.4049\/jimmunol.137.4.1329","article-title":"The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing","volume":"137","author":"Tesh","year":"1986","journal-title":"J\u00a0Immunol"},{"issue":"2","key":"2025032715214569100_bib31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/infdis\/159.2.195","article-title":"Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease","volume":"159","author":"Brandtzaeg","year":"1989","journal-title":"J\u00a0Infect Dis"},{"issue":"11","key":"2025032715214569100_bib32","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood.2023021231","article-title":"Low-frequency inherited complement receptor variants are associated with purpura fulminans","volume":"143","author":"Bendapudi","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2025032715214569100_bib33","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1055\/s-0044-1786356","article-title":"Limb ischemic necrosis secondary to microvascular thrombosis: a brief historical review","volume":"50","author":"Warkentin","year":"2024","journal-title":"Semin Thromb Hemost"},{"key":"2025032715214569100_bib34","first-page":"26","volume-title":"StatPearls","author":"Karki","year":":2023"},{"issue":"4","key":"2025032715214569100_bib35","doi-asserted-by":"crossref","first-page":"R156","DOI":"10.1186\/cc9226","article-title":"Human protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patients","volume":"14","author":"Veldman","year":"2010","journal-title":"Crit Care"},{"issue":"2","key":"2025032715214569100_bib36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1365-2141.1999.01186.x","article-title":"Infectious purpura fulminans: diagnosis and treatment","volume":"104","author":"Smith","year":"1999","journal-title":"Br J Haematol"},{"issue":"9091","key":"2025032715214569100_bib37","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(97)06356-3","article-title":"Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans","volume":"350","author":"Smith","year":"1997","journal-title":"Lancet"},{"issue":"7","key":"2025032715214569100_bib38","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1097\/00003246-200007000-00032","article-title":"Protein C substitution in sepsis-associated purpura fulminans","volume":"28","author":"Rintala","year":"2000","journal-title":"Crit Care Med"},{"issue":"1","key":"2025032715214569100_bib39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.thromres.2014.04.019","article-title":"Non-activated plasma-derived PC improves amputation rate of children undergoing sepsis","volume":"134","author":"Piccin","year":"2014","journal-title":"Thromb Res"},{"issue":"4","key":"2025032715214569100_bib40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1055\/s-2007-1000658","article-title":"Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency","volume":"21","author":"Dreyfus","year":"1995","journal-title":"Semin Thromb Hemost"},{"issue":"22","key":"2025032715214569100_bib41","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","article-title":"Drotrecogin alfa (activated) in adults with septic shock","volume":"366","author":"Ranieri","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2025032715214569100_bib42","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2025032715214569100_bib43","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1182\/blood.V96.12.3719","article-title":"An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia","volume":"96","author":"White","year":"2000","journal-title":"Blood"},{"issue":"4","key":"2025032715214569100_bib44","doi-asserted-by":"crossref","first-page":"R331","DOI":"10.1186\/cc3538","article-title":"Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies","volume":"9","author":"Vincent","year":"2005","journal-title":"Crit Care"},{"issue":"15","key":"2025032715214569100_bib45","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1001\/jama.286.15.1869","article-title":"Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial","volume":"286","author":"Warren","year":"2001","journal-title":"JAMA"},{"issue":"3","key":"2025032715214569100_bib46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/vox.13567","article-title":"New plasma protein C and protein S concentrate: a synergy for therapeutic purposes","volume":"119","author":"Mori","year":"2024","journal-title":"Vox Sang"},{"issue":"3","key":"2025032715214569100_bib47","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/CCM.0000000000000763","article-title":"The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis","volume":"43","author":"Zarychanski","year":"2015","journal-title":"Crit Care Med"},{"issue":"23","key":"2025032715214569100_bib48","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM196706082762304","article-title":"Sequential coagulation studies in purpura fulminans","volume":"276","author":"Antley","year":"1967","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2025032715214569100_bib49","first-page":"2386","article-title":"Ischemic limb gangrene with\u00a0pulses","volume":"373","author":"Warkentin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2025032715214569100_bib50","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1538-7836.2007.02485.x","article-title":"Thrombin as procoagulant and anticoagulant","volume":"5","author":"Di Cera","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2025032715214569100_bib51","first-page":"191","article-title":"Oral direct thrombin inhibition: a double-edged sword?","volume":"7","author":"Fragasso","year":"2015","journal-title":"Heart Lung Vessel"},{"issue":"12","key":"2025032715214569100_bib52","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.amjcard.2013.08.027","article-title":"Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors","volume":"112","author":"Artang","year":"2013","journal-title":"Am J Cardiol"},{"issue":"7","key":"2025032715214569100_bib53","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/jth.12591","article-title":"Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in\u00a0vitro and in\u00a0vivo","volume":"12","author":"Perzborn","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"16","key":"2025032715214569100_bib54","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJMc2021690","article-title":"Colloid transfusion, natural anticoagulant depletion, and symmetric peripheral gangrene","volume":"383","author":"Warkentin","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2025032715214569100_bib55","first-page":"149","article-title":"Prothrombin complex concentrates: an update","volume":"8","author":"Franchini","year":"2010","journal-title":"Blood Transfus"},{"issue":"1","key":"2025032715214569100_bib56","doi-asserted-by":"crossref","first-page":"e0170152","DOI":"10.1371\/journal.pone.0170152","article-title":"Fever is associated with reduced, hypothermia with increased mortality in septic patients: a meta-analysis of clinical trials","volume":"12","author":"Rumbus","year":"2017","journal-title":"PLoS One"},{"issue":"19","key":"2025032715214569100_bib57","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1182\/blood-2015-02-355974","article-title":"Activated protein C: biased for translation","volume":"125","author":"Griffin","year":"2015","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/13\/1358\/2362874\/blood_bld-2024-025078-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/13\/1358\/2362874\/blood_bld-2024-025078-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T12:32:11Z","timestamp":1743078731000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/13\/1358\/534864\/How-I-diagnose-and-treat-acute-infection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":57,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,3,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025078","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]}}}